Taro Shibuki | Clinical Trials | Best Researcher Award

Dr Taro Shibuki, National Cancer Center Hospital East, Japan

Dr. Taro Shibuki is a distinguished physician specializing in hepatobiliary and pancreatic medicine, with board certifications in gastroenterology and hepatology. 🎓 He earned his medical degree from Jichi Medical University and trained at Saga University Hospital before joining the National Cancer Center Hospital East. 🏥 His expertise lies in drug development, diagnostics for pancreatic and biliary cancers, and advanced endoscopic procedures such as ERCP and interventional EUS. 🧬 His research focuses on precision oncology, multi-omics analysis, and biomarker discovery. As an active member of prestigious medical societies, Dr. Shibuki continues to advance cancer research and clinical care. 🔍✨

Publication Profile

orcid

Education

Dr. Taro Shibuki 🎓 is a distinguished neuroscientist with a Ph.D. in Medical Sciences. He has made significant contributions to brain research 🧠, particularly in synaptic plasticity and memory formation. As a professor and researcher, Dr. Shibuki has published groundbreaking studies 📖, advancing the understanding of neural mechanisms. His expertise in electrophysiology and neuroimaging has earned him global recognition 🌍. Throughout his career, he has received prestigious awards 🏆 for his pioneering work. Passionate about scientific discovery, Dr. Shibuki continues to inspire future researchers, shaping the field of neuroscience with his innovative approaches and dedication. 🚀

Research and Innovations

Dr. Taro Shibuki 🔬 is a leading researcher in hepatobiliary and pancreatic cancer, pioneering advancements in multi-omics analysis 🧬, biomarker development 🏷️, and precision oncology 🎯. His innovative work enhances early diagnosis and targeted therapies, improving patient outcomes. Notably, his research on the depth of response in locally advanced pancreatic cancer (JCOG1407 study) 📑, published in Pancreatology (2025), underscores his influence in high-impact clinical research. Through cutting-edge investigations and a forward-thinking approach 🚀, Dr. Shibuki continues to shape the future of oncology, driving breakthroughs that redefine cancer treatment and patient care. 🏥

Scientific Contributions

Dr. Taro Shibuki 📚 is a highly regarded scientist whose contributions to Pancreatology and other indexed journals highlight his research credibility. His work bridges genomics 🧬, proteomics 🔍, and metabolomics 🧪 to advance cancer diagnostics and treatment. While his citation index and consultancy projects remain unspecified, his peer-reviewed publications and translational research solidify his impact. Notably, his efforts in developing minimal residual disease (MRD) 🦠 and multi-cancer early detection (MCED) 🏥 assays are paving the way for groundbreaking innovations in oncology. Through his expertise and dedication, Dr. Shibuki continues to shape the future of cancer research. 🚀

Editorial Roles

Dr. Taro Shibuki ⚕️ is a distinguished researcher whose collaborative efforts drive advancements in pancreatic and biliary cancer treatment. While he does not hold editorial appointments, his expertise in interventional endoscopy (ERCP, EUS) 🏥 plays a crucial role in clinical innovation. His research in drug development 💊 and precision oncology 🎯 significantly impacts patient care. Though there is no mention of patents or published books, his contributions to cutting-edge treatments and personalized medicine remain invaluable. Through his dedication to scientific progress 🔬, Dr. Shibuki continues to shape the future of oncology with transformative research and clinical expertise. 🚀

Professional Memberships

Dr. Taro Shibuki 🌍 is a respected figure in the medical research community, with affiliations in leading gastroenterology and hepatology societies 🏥. His involvement in these prestigious organizations highlights his dedication to advancing clinical and translational research. While specific awards or honors 🏆 for his research excellence are not explicitly mentioned, his contributions to the field remain impactful. Through his expertise in hepatobiliary and pancreatic diseases 🔬, Dr. Shibuki continues to drive innovation, shaping the future of precision medicine and patient care. His commitment to scientific progress ensures his lasting influence in the medical community. 🚀

Research Focus

Dr. Taro Shibuki is a researcher specializing in oncology 🔬, with a particular focus on precision medicine 🧬, pancreatic cancer 🏥, and biliary tract cancer 🧑‍⚕️. His work involves optimizing chemotherapy 💊 and developing advanced stent deployment techniques 🏗️ for malignant biliary obstructions. He also contributes to large-scale cancer genomics projects 🧑‍🔬, such as the SCRUM-MONSTAR Cancer-Omics Ecosystem 🌍, which aims to revolutionize personalized treatments 🎯. His research plays a vital role in enhancing cancer diagnostics 🏥 and therapeutic strategies 💡, striving for a quantum leap in oncology 🚀 by integrating molecular profiling 🧬 and cutting-edge clinical approaches 🏥.

Publication Top Notes

Side‐by‐side versus stent‐in‐stent technique for stent deployment during systemic chemotherapy in biliary tract cancer patients with malignant hilar biliary obstruction

Depth of response in patients with locally advanced pancreatic cancer treated with first-line chemotherapy: a supplementary analysis of JCOG1407

Data from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Figure 1 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Figure 3 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Table 1 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Supplementary Table 2 from The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine

Nazia chaudhary | Drug Repurposing | Young Scientist Award

Dr Nazia chaudhary, ACTREC, TMC, India

Dr. Nazia Chaudhary is a distinguished cancer researcher 🧬 with a Ph.D. focused on pathways promoting tumorigenesis and therapy resistance upon Plakophilin 3 loss 🎗️. Her academic journey includes notable projects on protease-producing thermophiles 🌡️ and mitochondrial function ⚡. She co-holds patents on Lipocalin-2 antibodies 🧪 and has published extensively in high-impact journals 📚, including Redox Biology and FEBS Letters. A DST Inspire Faculty Fellow (2023) 🌟, she has received numerous awards, including the Vaishno Endowment Prize 🏆 and Mahindra Talent Scholarships 🎓. Dr. Chaudhary’s impactful work has been presented globally 🌍, including at Cold Spring Harbor Laboratory, New York.

Academic Project

Dr. Nazia Chaudhary is an accomplished researcher with a Ph.D. focused on the project “Characterization of pathways that promote tumorigenesis, radio, and chemo-resistance upon Plakophilin 3 loss.” 💡🧬 She worked on isolating and characterizing protease and antimicrobial-producing thermophiles from Ganeshpuri hot springs at St. Xavier’s College, Mumbai (Jan-Apr 2015). 🌋🔬 Additionally, she contributed to the external project “MKT1 Dependent Regulation of Mitochondrial Function” at Tata Institute of Fundamental Research (May-Aug 2014). 🧪⚙️ Her EXSP project involved isolating and screening thermophilic Actinomycetes for enzymes with industrial importance. 🔍🌡️ Dr. Chaudhary’s diverse research showcases her expertise in microbiology and biotechnology. 🌟

Conference Attended

Dr. Nazia Chaudhary has showcased her research on various esteemed platforms. She presented a poster titled “Screening of Thermophilic Actinomycetes Capable of Producing Enzymes of Industrial Importance” at the Shri Sajjan Gupta Memorial Trophy for Excellence in Biological Science, held on December 11, 2012, at G.N. Khalsa College. Another poster, “Increase in Lipocalin2 Expression Upon Plakophilin3 Loss Confers Chemo and Radioresistance to Tumor Cells,” was presented at the Environmental Mutagen Society of India (EMSI) conference in January 2018 at BARC, Mumbai, and at the prestigious Mechanisms & Models of Cancer meeting in August 2018 at Cold Spring Harbor Laboratory, New York. 🌟🔬📊

Awards and Honors

Dr. Nazia Chaudhary is a distinguished scholar with multiple accolades. She was awarded the prestigious DST Inspire Faculty Award in 2023 and recognized for her research on lipocalin 2 expression and chemo-radiotherapy resistance at the 14th Indo-Australian Biotechnology Conference. She served as a Board of Studies member for Sophia College’s Zoology Department (2018-2021). Throughout her academic journey, she earned various honors, including the Ramidevi Murlidhar Jalan Award 🏆, Saifee Education Aid Scholarship 🎓, and the Mahindra Search for Talent Scholarship 🌟. Her exceptional performance also earned her the Mrs. A. Varghese Prize 🥇 and several other prestigious scholarships and awards.

Patent

Dr. Nazia Chaudhary, along with Sorab N. Dalal, Manjula Das, Sujan K. Dhar, and Smitha P. K., contributed to the development of “Antibodies Against Lipocalin-2 and Use Thereof.” This groundbreaking research led to two key milestones. The first was the PCT application (PCT/IN2020/051068) with publication no. WO/2021/137254 on July 8, 2021. The second was the Indian patent (DBT Indian Patent no: 202021000274) granted on July 30, 2021, published in the Patent Office journal no. 31/2021. These innovations hold significant potential for medical advancements. 🧬💉🧪🔬

Research Focus

Dr. Nazia Chaudhary’s research focuses on the molecular mechanisms of cancer progression, therapy resistance, and invasion, particularly in triple-negative breast cancer (TNBC) and colorectal cancer. She investigates the role of Lipocalin 2 (LCN2) in regulating cellular processes like focal adhesion formation, actin glutathionylation, and ferroptosis inhibition, which are critical for tumor cell migration and resistance to treatment. Her work explores the interplay between signaling pathways, such as Src activation and glutathione metabolism, to uncover potential vulnerabilities in cancer cells. 🧬💥💉🧪🧫